Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure

NCT00338000 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT00338000
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00338000 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 4
Overall status
Completed
Start date
June 30, 2001
Completion date
May 31, 2005
Enrollment
292 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic renal failure